Description
MotesanibisaninhibitorofVEGFR1/2/3,PDGFR,c-Kit,andRETthatdisplaysanticancerchemotherapeuticandanti-angiogenicactivities.Invivo,motesanibinhibitstumorgrowthofxenograftsofvariouscancers.Motesanibiscurrentlyinclinicaltrialsasapotentialtreatmentfornon-smallcelllungcancer(NSCLC),breastcancer,andmedullarythyroidcancer.
References
EllisPM,Al-SalehK.Multitargetedanti-angiogenicagentsandNSCLC:clinicalupdateandfuturedirections.CritRevOncolHematol.2012Oct;84(1):47-58.PMID:22405734.
CoxonA,ZieglerB,KaufmanS,etal.Antitumoractivityofmotesanibaloneandincombinationwithcisplatinordocetaxelinmultiplehumannon-small-celllungcancerxenograftmodels.MolCancer.2012Sep19;11:70.PMID:22992329.
CoxonA,BreadyJ,KaufmanS,etal.Anti-tumoractivityofmotesanibinamedullarythyroidcancermodel.JEndocrinolInvest.2012Feb;35(2):181-90.PMID:21422803.
RaghavKP,BlumenscheinGR.MotesanibandadvancedNSCLC:experiencesandexpectations.ExpertOpinInvestigDrugs.2011Jun;20(6):859-69.PMID:21534718.
PolverinoA,CoxonA,StarnesC,etal.AMG706,anoral,multikinaseinhibitorthatselectivelytargetsvascularendothelialgrowthfactor,platelet-derivedgrowthfactor,andkitreceptors,potentlyinhibitsangiogenesisandinducesregressionintumorxenografts.CancerRes.2006Sep1;66(17):8715-21.PMID:16951187.